News
University Hospital of Bellvitge receives the third consecutive Top 20 award for best management
University Hospital of Bellvitge has been awarded for the third consecutive year and fifth time during its history (2004, 2006, 2009, 2010 and 2011), as one of the best hospitals in Spain.
Scientists discover an epigenetic alteration in breast cancer that predicts lack of response to some chemotherapy treatments
Researchers from IDIBELL have collaborated on a study characterizes a protein called RBM38, key in the regulation of tumor cell death, which is disabled in breast tumors, making them more resistant to some chemotherapy treatments. Practical application Article’s reference
Bioinformatics, systems biology and functional genomics, protagonists at IDIBELL
IDIBELL hosted DREAM, RECOMB and RICCI conferences on October 14 -19th On October 14 -19 IDIBELL has hosted the 6th Annual DREAM on Reverse Engineering Challenges, the 7th Annual RECOMB Satellite on Systems Biology and the 8th Annual RECOMB on Regulatory Genomics , which were first held outside the U.S.
A multicenter trial will allow marketing a genetic test for endometrial cancer
The University Hospital of Bellvitge and IDIBELL coordinate the clinical trial which included over 500 patients
Playmancer project, awarded as the best European serious game on health
IDIBELL researchers and professionals of the Psychiatry Service of the Bellvitge University Hospital have been awarded the prize for best European serious game on health category for the therapeutic videogame: Playmancer. The award will be presented in the course of the Fun & Serious Game Festivalthat will take place on 8 and 9 November in […]
Colon tumor cells that metastasize to the liver become more aggressive in response to a new hostile microenvironment
Most malignant cells die; only survive those who adapt better Certain healthy liver cells promote an adaptive response in colorectal cancer cells by inhibiting proliferation and causing their death. Tumor cells, that adapt themselves to new conditions, change their behavior and morphology, favoring migration. Researchers from the IDIBELL and the Catalan Institute of Oncology (ICO), coordinated by David Garcia Molleví have published the results of this study in the journal Neoplasia . A hostile microenvironment Article’s reference
IDIBELL and Cedars-Sinai join efforts for technology transfer
Cedars-Sinai Medical Center (Los Angeles) and IDIBELL have signed an agreement of cooperation on technology transfer. The agreement suppose the mutual support to increase technology transfer activities as well as access to the U.S. market for the commercialization of products or technologies developed by IDIBELL.
IDIBELL joins the UN Global Compact
IDIBELL has signed the Global Compact of the United Nations Organization. This is an initiative that aims at a voluntary commitment to social responsibility on the part of the signatories from around the world.
Antonis Antoniou: “More than 1,500 users worldwide use Boadicea model to predict risk of breast cancer”
“Boadicea was the name of a British soldier who fought the Roman invasion. Now is also the name of a new tool to combat the new enemy: cancer.” The researcher of the University of Cambridge, Antonis Antoniou, explained at the IDIBELL seminar on 30 September his latest advances in the development of genetic models, such […]